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Transplantation: Comparison of Double Umbilical
Cord Blood and Unrelated Donor Grafts
Yi-Bin Chen,1 Julie Aldridge,2 Haesook T. Kim,2 Karen K. Ballen,1 Corey Cutler,3 Grace Kao,3
Deborah Liney,3 Greg Bourdeau,3 Edwin P. Alyea,3 Philippe Armand,3 John Koreth,3
Jerome Ritz,3 Thomas R. Spitzer,1 Robert J. Soiffer,3 Joseph H. Antin,3 Vincent T. Ho3There are little data comparing umbilical cord blood (UBC) and conventional stem cell sources for reduced-
intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT). We performed a retrospective
analysis of RIC HCSTusing double UCB (dUCB) grafts and RIC HSCTusing unrelated donor (URD) grafts.
The study included 64 dUCB transplantations and 221 URD transplantations performed at Dana-Farber
Cancer Institute and Massachusetts General Hospital between 2004 and 2008. The cumulative incidence
of grade II-IV acute graft-versus-host disease (GVHD) was 14.1% for dUCB and 20.3% for URD (P 5 .32).
The 2-year cumulative incidence of chronic GVHD was significantly lower in dUCB compared with URD
(21.9% versus 53.9%; P\.0001). The 2-year cumulative incidence of nonrelapse mortality was significantly
higher in dUCB (26.9% versus 10.4%; P 5 .0009). In our analysis, dUCB HSCTand URD HSCT had compa-
rable 3-year overall survival (46% in dUCB and 50% in URD; P 5 .49) and progression-free survival (30% in
dUCB and 40% in URD; P 5 .47). dUCBT was associated with greater nonrelapse mortality despite less
chronic GVHD. Our findings suggest that the use of 2 partially matched UCB units appears to be a suitable
alternative for patients undergoing RIC HSCTwithout an HLA-matched donor.
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In the last decade, umbilical cord blood (UCB) has
emerged as a viable stemcell source for allogeneichema-
topoietic stem cell transplantation (HSCT) in adult pa-
tientswho lack awell-matched relatedorunrelated adult
donor [1]. With increasing experience and advances in
supportive care, outcomes after UCB transplantation
(UCBT) have improved [2]. In the setting ofmyeloabla-
tive conditioning regimens, 2 recent large retrospective
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6/j.bbmt.2011.10.016adult unrelated donor (URD) peripheral blood stem
cell (PBSC) or bone marrow (BM) transplantation for
adult patients with hematologic malignancies [3,4].
In related and unrelated PBSC transplantation,
reduced-intensity conditioning (RIC) regimens
achieve reliably high rates of engraftment with accept-
able toxicity. RIC regimens thus make allogeneic
hematopoietic stem cell transplantation (HSCT)
feasible for patients previously considered ineligible
because of older age or medical comorbidities. A con-
cern with RIC regimens in UCBT has been that insuf-
ficient conditioning intensity might not allow reliable
engraftment, particularly in UCBT, in which hemato-
poietic progenitor cell numbers are lower relative to
HSCT with adult stem cell sources. The advent of
new strategies such as the use of 2 partially matched
UCB units (ie, double UCBT [dUCBT]) and ongoing
development of in vitro UCB stem cell expansion,
along with the publication of several series of success-
ful RIC UCBT [5-8] have promoted the increased
adoption of RIC regimens in UCBT.
To date, there have been no published studies
comparing outcomes between UCBT and unrelated
donor HSCT after RIC.We undertook a retrospective805
806 Biol Blood Marrow Transplant 18:805-812, 2012Y.-B. Chen et al.analysis at our institutions comparing patients with
advanced hematologic malignancies undergoing RIC
HSCT using stem cells fromUCB and patients under-
goingRICHSCTusing stem cells from adult unrelated
donors.METHODS
Patients and Supportive Care
All patients undergoing RIC HSCT using either
UCB stem cells or stem cells from well-matched
unrelated adult donors between January 1, 2004, and
December 30, 2008, at Dana-Farber/Brigham and
Women’s Cancer Center and Massachusetts General
Hospital Cancer Center were included. These centers
share UCBT clinical protocols and work under a com-
mon Institutional Review Board. For patients who
underwent more than one RIC HSCT, only the first
transplantation was considered in this analysis. The
choice to use RIC was based on the physician’s judg-
ment, the underlying disease, disease status, and the
patient’s age and comorbidities. In general, at our in-
stitutions, RIC regimens are recommended for pa-
tients age .60 years when using URD stem cells and
patients age .30 years when using UCB. UCB units
for all of the 64 patients receiving RIC dUCBT were
at least 4/6 HLA matched (allele-level typing at
HLA-A, -B, and -DRB1) with each other and with
the recipient. Each UCB unit had at least 1.5 107 to-
tal nucleated cells/kg recipient weight, with the sum of
the 2 units at least 3.7  107 total nucleated cells/kg.
URD grafts were 7/8 or 8/8 HLA allele-level matched
(HLA-A, -B, -C, and -DRB1). Eligibility for trans-
plantation, conditioning regimens, and supportive
care were similar in the 2 centers and included inpa-
tient hospitalization in single hospital rooms with
high-efficiency particulate air filtration. Antiviral pro-
phylaxis against herpes simplex/varicella zoster virus
and Pneumocystis jirovecii prophylaxis was continued
for at least 1 year after HSCT. Cytomegalovirus was
monitored routinely after HSCT and treated preemp-
tively. In patients who underwent dUCBT, Epstein-
Barr virus (EBV) and human herpesvirus 6 also were
monitored routinely. All patients provided consent
for use of protected health data for research as ap-
proved by our Institutional Review Board.
Engraftment and Graft-versus-Host Disease
Neutrophil engraftment was defined as an absolute
neutrophil count (ANC) .500/mL on 3 consecutive
measurements. Platelet recovery was defined as 2
consecutive measurements of .20,000/mL unsup-
ported. Graft-versus-host disease (GVHD) prophy-
laxis regimens are described below. Tapering of
immune suppression was initiated at 2-4 months after
transplantation, with the goal of cessation by approxi-mately 6 months in the absence of GVHD. No pre-
emptive or planned prophylactic donor lymphocyte
infusions (DLI) were given. Acute GVHD was graded
using consensus grading criteria [9], and cumulative
incidence was calculated through day 200 post-
HSCT, given that acute GVHD often presents after
day 100 in patients undergoing RIC HSCT. Chronic
GVHD was defined clinically by the treating physi-
cians; grading of the severity of chronic GVHD was
not included in this analysis because of the recent
changes in the classification scheme [10].
Chimerism Analysis
Total donor chimerism was assessed from periph-
eral blood samples at approximately day 130 (range,
day 120 to day 150) and day 1100 (range, day 190
to day 1120) after HSCT. Chimerism was not rou-
tinely analyzed from BM samples. Genotyping was de-
termined by short tandem repeat typing using the ABI
Profiler Plus Kit and ABI 310 Genetic Analyzer (Ap-
plied Biosystems, Bedford, MA). ‘‘Informative’’
alleles specific to the donor or recipient were used
for chimerism determination.
Statistical Analysis
Descriptive statistics were used to summarize
patient characteristics. The Wilcoxon rank sum test,
c2 test, or Fisher exact test was used for 2-sample com-
parisons. Cumulative incidence curves for GVHD
were constructed, reflecting death or relapse without
development of GVHD as a competing risk. Cumula-
tive incidence curves for relapse and nonrelapse mor-
tality (NRM) were constructed, reflecting time to
relapse and time to nonrelapse death as competing
risks. The difference between cumulative incidence
curves in the presence of a competing risk was tested
using the method of Gray [11]. Time to relapse and
time to nonrelapse death were measured from the
date of stem cell infusion.
Overall survival (OS) and progression-free survival
(PFS) were calculated by the Kaplan-Meier method.
OS was defined as the time from stem cell infusion
to death from any cause; PFS, as the time from stem
cell infusion to relapse, disease progression, or death
from any cause. The log-rank test was used to compare
Kaplan-Meier curves.
Potential prognostic factors for OS, PFS, relapse,
and NRM were examined in a Cox proportional
hazards model and a competing-risks regression
model [12]. Variables examined in the multivariate
models included stem cell source (dUCB versus URD),
age ($50 years versus \50 years), patient–donor sex
mismatch (M/F versus other), previous autologous
stem cell transplantation, disease risk status, disease
(myeloid versus lymphoid),GVHDprophylaxis regimen
(sirolimus versus no sirolimus), and year of HSCT.
Table 1. Patient Characteristics
dUCB,
n (%)
URD,
n (%)
P
Value
Number of patients (%) 64 (100) 221 (100)
Age, years, median (range) 53 (19-67) 58 (19-73) .004
Age $50 years, n (%) 36 (56) 176 (80) .0003
Age <50 years, n (%) 28 (44) 45 (20)
Donor age, years, median (range) – 32 (18-60)
Previous autologous SCT, n (%) 20 (31) 64 (29) .76
Underlying diagnosis, n (%) .11
AML 23 (36) 72 (33)
Non-Hodgkin lymphoma 17 (27) 32 (14)
MDS 7 (11) 36 (16)
CLL/SLL/PLL 4 (6) 34 (15)
Hodgkin’s lymphoma 7 (11) 20 (9)
Acute lymphoblastic leukemia 3 (5) 4 (2)
CML 2 (3) 8 (4)
Multiple myeloma – 7 (3)
Myeloproliferative disease 1 (2) 8 (4)
Disease risk status, n (%) .20
High risk 39 (61) 113 (51)
Standard risk 25 (39) 108 (49)
GVHD prophylaxis, n (%)
Tacrolimus/sirolimus 41 (64) –
Tacrolimus/sirolimus ±
mini-MTX
– 152 (69)
Tacrolimus/mini-MTX–based – 51 (23)
Cyclosporine or
tacrolimus/MMF
23 (36) 4 (2)
Ex vivo TCD/tacrolimus-based – 8 (4)
Tacrolimus/bortezomib/MTX – 6 (3)
Conditioning regimen, n (%)
Fludarabine/busulfan 6.4 mg/kg* 1 (2) 25 (11)
Fludarabine/busulfan 3.2 mg/kg – 196 (89)
Fludarabine/melphalan/ATG 63 (99) –
Cell source, n (%)
BM – 7 (3)
PBSC – 214 (97)
Cord blood 64 (100) –
HLA matching: URD, n (%)
Match at HLA-A, -B, -DRB1 – 221 (100)
Mismatch at HLA-A, -B, -DRB1 – –
Match at HLA-C – 201 (91)
HLA matching: dUCB, n (%)†
4/6 + 4/6 47 (73) –
4/6 + 5/6 12 (19) –
5/6 + 5/6 5 (8) –
Cell dose, median (range)
Total nucleated cells  108/kg 0.44 (0.1-0.85) –
CD34+ cells/kg  106/kg 0.26 (.02-1.15) 8.53 (0.26-47.7)
SLL indicates small lymphocytic lymphoma; PLL, prolymphocytic leuke-
mia; MMF, mycophenolate mofetil.
*Five patients who received fludarabine/busulfan 6.4 mg/kg also received
rabbit ATG during conditioning.
†HLA matching for patients undergoing dUCB is given as out of 6 anti-
gens (HLA-A, -B, and -DRB1).
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elogenous leukemia (AML) or chronicmyelogenous leu-
kemia (CML) beyond first complete remission or first
chronic phase, myelodysplastic syndrome (MDS) other
than de novo refractory anemia/refractory anemia with
ringed sideroblasts, and chronic lymphocytic leukemia
(CLL)/lymphoma/multiple myeloma not in remission
at the time of transplantation [13]. Patients not defined
as high risk were classified as standard risk. Because the
baseline characteristics were imbalanced between the 2
cohorts, propensity score analysis [14] was applied tothe multivariate Cox model and competing-risks regres-
sion model to reduce the selection bias. Proportional
hazards assumption was examined in each model. All
tests were 2-sided. The analyses were performed using
SAS version 9 (SAS Institute, Cary, NC) and R.2.10.1
(R Foundation for Statistical Computing, Vienna,
Austria).RESULTS
Patient and Transplant Characteristics
Characteristics of the 285 patients included in this
study are summarized in Table 1. The median patient
age was 53 years (range, 19-67 years) for the dUCB
group and 58 years (range, 19-73 years) for the URD
group (P 5 .004). Patients age $50 years composed
56%of the dUCBTgroup and 80%of theURD group
(P 5 .0003). The 2 cohorts were balanced in terms of
sex, diseases, disease risk, and previous autologous
stem cell transplantation (31% in the dUCB group
and 29% in the URD group; P 5 .76). Patients who
had undergone previous allogeneic stem cell trans-
plantation were excluded from this analysis. Of the
221 patients undergoing URD HSCT, 201 (91%)
were 8/8 HLA matched by allelic typing, and
20 (9%) were 7/8 matched. All mismatches were at
HLA-C. Seven patients (3%) underwent URD trans-
plantation with BM, and 214 (97%) received PBSCs.
Conditioning for RIC dUCBT consisted of fludara-
bine (30 mg/m2 for 5 days)/melphalan (100 mg/m2
for 1 day)/antithymocyte globulin (ATG; 1.5 mg/kg
for 4 days), as described previously [5,8]. RIC with
URD HSCT consisted of fludarabine (30 mg/m2 for
4 days) with low-dose i.v. busulfan (3.2 mg/kg total)
in 89% of patients and intermediate-dose i.v. busulfan
(6.4 mg/kg total) in 11%. Five patients who received
intermediate-dose fludarabine/busulfan also received
ATG during conditioning. GVHD prophylaxis for
dUCBT was cyclosporine/mycophenolate mofetil in
36% of the patients and tacrolimus/sirolimus in
64%. In URD recipients, GVHD prophylaxis was
tacrolimus/sirolimus 6 mini-methotrexate (MTX)
(5 mg/m2 on days 1, 3, 6, 6 11) in 69%, tacrolimus/
mini-MTX–based in 23%, and other regimens in 8%
(Table 1). Median follow-up for survivors was 43.4
months (range, 5.5-66.2 months) in the dUCB group
and 36.8 months (range, 11.6-81.0 months) in the
URD group.
Engraftment, GVHD, and Chimerism
As shown in Table 2, median times to neutrophil
and platelet recovery were both significantly longer
in the dUCBT group compared with the URD group.
All patients undergoing RIC dUCBT experienced an
ANC nadir of\500/mL, compared with only 55% of
the URD group. The rate of successful neutrophil
Table 2. Outcomes of Neutrophil and Platelet Engraftment
dUCB URD P Value
Neutrophil engraftment, %* 92 99.5 <.0001
Time to neutrophil engraftment, days, median (range)† 21.5 (13-70) 13 (2-181) <.0001
Neutrophil engraftment by day +50 post-HSCT, % 85.9 98.6 .0003
Platelet recovery, %‡ 75.0 96.8 <.0001
Time to platelet recovery, days, median (range)§ 41 (9-185) 19 (9-169) <.0001
Platelet recovery by day +100 post-HSCT, % 56.3 94.5 <.0001
Note that 45% (n 5 99) of patients in the URD cohort did not experience a nadir of ANC <500/mL and thus were not included in this analysis when
calculating median time to engraftment.
*Neutrophil engraftment was defined as an ANC >500/mL on 3 consecutive measurements.
†Time to neutrophil engraftment defined as the first day of 3 consecutive measurements of ANC >500/mL.
‡Platelet recovery defined as 2 consecutive measurements of >20,000/mL unsupported.
§Time to Platelet recovery defined as the first day of 2 consecutive measurements of > 20,000/mL unsupported.
808 Biol Blood Marrow Transplant 18:805-812, 2012Y.-B. Chen et al.engraftment was lower in the dUCBT group (92%
versus 99.5%; P\ .0001). By day 150 after HSCT,
85.9% the dUCB group and 98.6% of the URD group
demonstrated neutrophil engraftment (P 5 .0003). By
day 1100, platelet recovery was observed in 56.3% of
dUCBT recipients and 94.5% ofURD recipients (P\
.0001).
Despite the greater HLA disparity between donors
and recipients in the dUCBT cohort, this group did
not have a significantly higher cumulative incidence
of grade II-IV acute GVHD compared with the
URD group (cumulative incidence at day 200, 14.1%
in dUCB versus 20.3% in URD; P 5 .32) (Figure 1).
The cumulative incidence of grade III-IV acute
GVHD was 3.1% in the dUCB group and 6.8% in
the URD group (P5 .29). The dUCB group had a sig-
nificantly lower cumulative incidence of chronic
GVHD (21.9% versus 53.9%; P\ .0001) (Figure 2).
Results of peripheral blood chimerism studies were
available at day 130 (range, day 120-day 150) for 38
patients (59%) in the dUCB group and 199 patients
(90%) in the URD group. Mixed chimerism, defined0 50 100 150 200
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Figure 1. Cumulative incidence of grade II-IV acute GVHD. Cumulative
incidence at 200 days was 14.1% in dUCB and 20.3% in URD groups (P5
.32).as\90% donor chimerism in unseparated cell analysis
(in dUCBT,\90% of combined donor UCB chime-
rism), was present in 29% of the dUCBT group and
30% of the URD group (P 5 .69) (data not shown).
Analysis performed at day 1100 in both groups found
no significant differences in results.
Disease Relapse and NRM
At 3 years, the cumulative incidence of disease
relapse was 42.7% in the dUCB group and 49.8% in
the URD group (P 5 .09) (Table 3 and Figure 3).
The 3-year cumulative incidence of NRM was higher
in the dUCBT group (26.9% versus 10.4%;
P 5 .0009). The results of propensity score-adjusted
multivariate competing-risks regression analysis for
relapse andNRMare given inTable 4. In themultivar-
iate model, donor type (dUCB versus URD) was not
a factor for disease relapse, but the use of dUCB was
a significant independent factor associated with
NRM (hazard ratio, 3.55; 95% confidence interval,
1.82-6.92; P 5 .0002). There were 16 cases of
NRM in the dUCBT group. Infection and EBV-
posttransplantation lymphoproliferative disease
(PTLD) associated complications were the most
common causes of NRM after RIC dUCBT
(Figure 4). There also were 2 cases of intracranial hem-
orrhage and 2 cases of fatal donor cell–derived malig-
nancies [15]. GVHD and associated complications
were responsible for only 1 death in the dUCBT
group. In our multivariate competing-risks regression
analysis for patients undergoing dUCBT, only patient
age was a significant factor for NRM (data not shown).
Survival
PFS and OS were not statistically significantly dif-
ferent between the dUCB and URD groups. Three-
year PFS was 30% in the dUCBT group and 40% in
the URD group (P 5 .47) (Table 2 and Figure 5),
and 3-year OS was 46% and 50%, respectively
(P 5 .49) (Table 2 and Figure 6). A propensity score-
adjusted multivariate analysis found no difference in
OS and PFS between the 2 groups (Table 4).
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Figure 2. Cumulative incidence of chronic GVHD. The 2-year cumula-
tive incidence of chronic GVHD was 21.9% in dUCB and 53.9% in URD
groups (P . .0001).
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To the best of our knowledge, this is the first pub-
lished retrospective analysis comparing dUCB and
URD as stem cell sources for patients undergoing
RIC allogeneic HSCT. All patients were treated at 2
institutions that share clinical protocols and have sim-
ilar practice standards. Our findings demonstrate com-
parable PFS and OS in RIC dUCBT and RIC HSCT
from well-matched adult URDs. However, dUCBT is
associated with slower engraftment and a significantly
higher rate of NRM, primarily from complications of
infection and EBV-PTLD, despite a significantly
lower incidence of chronic GVHD compared with
URD HSCT.
The Center for International Blood and Marrow
TransplantResearch (CIBMTR) reported similar find-
ings in an abstract of a registry analysis of 585 adult pa-
tients with acute leukemia (the majority with AML),
comparing outcomes between patients undergoing
RIC dUCBT and RIC URD HSCT [16]. Similar to
the present study, the CIBMTR analysis showed
higher transplantation-relatedmortality with dUCBT,Table 3. Summary of Outcomes
dUCB
(n 5 64)
URD
(n 5 221) P Value
Cumulative incidence of grade II-IV
acute GVHD
14.1% 20.3% .32
Cumulative incidence of grade III-IV
acute GVHD
3.1% 6.8% .29
2-year incidence of chronic GVHD 21.9% 53.9% <.0001
3-year cumulative incidence of relapse 42.7% 49.8% .09
3-year cumulative NRM 26.9% 10.4% .0009
3-year PFS 30% 40% .47
3-year OS 46% 50% .49but similar durable leukemia-free survival and OS in
the 2 groups, due to relatively lower rates of relapse
[16]. Investigators from the University of Minnesota
reported similar outcomes in a smaller study compar-
ing RIC dUCBT and RIC matched sibling donor
HSCT in patients with AML [17], and recently investi-
gators atMemorial Sloan-Kettering Cancer Center re-
ported similar OS in UCB, related donor, and URD
transplantations, but \25% of the patients in their
analysis were recipients of RIC regimens, and the study
population included children as well as adults [18].
In the setting of myeloablative HSCT, the
CIBMTR analyzed a total of 1525 patients (165 UCB
recipients, 888 URD PBSC recipients, and 472 URD
BM recipients) and reported similar leukemia-free
survival in single UCBT and URD HSCT.
Transplantation-related mortality was clearly higher
after UCBT; however, the incidence of chronic
GVHD was significantly lower in recipients of
UCBT [3]. In addition, a recent joint analysis by the
groups in Minnesota and Seattle found similar out-
comes after myeloablative HSCT, with recipients of
dUCBT having higher NRM and lower relapse rates
but similar overall outcomes compared with recipients
of adult BM and PBSC transplantations [4].
An intriguing aspect of the foregoing analyses is
the similar or lower relapse rates observed after
dUCBT compared with URD HSCT, despite the
lower incidence of chronic GVHD after dUCBT. In
the present study, the difference in relapse rates was
not statistically significant, whereas other studies
have suggested lower relapse rates after UCBT
[4,16]. The mechanism responsible for the similar or
lower relapse rates after dUCBT with less chronic
GVHD is unclear. The majority of UCB units in our
series were 4/6 HLA-matched, and perhaps this in-
creased degree of HLA mismatch led to a more potent
graft-versus-malignancy effect. However, in the Uni-
versity of Minnesota study, more than one-half of the
UCB units were 5-6/6 HLA-matched with recipients
[4]. Another possibility is that in the majority of pa-
tients who undergo dUCBT, one UCB unit eventually
becomes dominant, with subsequent rejection of the
other UCB unit. In other settings, graft rejection has
been associated with strong antitumor responses
[20,21]. Perhaps the rejection of 1 UCB unit
contributes to the observed lower relapse rates.
Indeed, there are data suggesting lower relapse rates
after dUCBT than after single UCBT [19]. It is also
possible that the graft-versus-malignancy effect after
UCBT is immunologically different than that after
adult URD HSCT; this is supported by the different
patterns of immune reconstitution seen in PBSC trans-
plantation and UCBT [22]. Preliminary analysis in our
dUCB cohort showed that the development of chronic
GVHD had no influence on relapse or PFS (data not
shown); however, given the small number of patients
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Figure 3. NRM and relapse. The 2-year cumulative incidence of NRM
was 25.1% in dUCB versus 7.3% in URD groups (P5 .0009). The 2-year
cumulative incidence of relapse was 39.3% in dUCB versus 48.5% in
URD groups (P 5 .09).
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ing conclusions from these data is difficult. Larger
studies are needed to define the influence of GVHD
on clinical outcomes after UCBT, and such an effort
is under way through the CIBMTR.
As seen in this and other studies, the use of UCB in
HSCT is associated with significantly higher rates of
NRM compared with the use of adult stem cell sour-
ces. As shown in Figure 4, the majority of NRM in
our series involved either EBV-PTLD or infectious
complications. This likely reflects both the delayed
immune reconstitution after dUCBT and the strong
immunosuppressive effects of our conditioning regi-
men, which included ATG. There is clear evidence
that the use of ATG in the conditioning regimen forTable 4. Propensity Score-Adjusted Multivariable Competing-
Risks RegressionModel for Relapse and NRM and CoxModel for
PFS and OS
HR 95% CI P Value
Relapse
dUCB versus URD 0.68 0.44-1.04 .08
Myeloid versus lymphoid 1.45 0.99-2.12 .06
NRM
dUCB versus URD 3.55 1.82-6.92 .0002
PFS
dUCB versus URD 1.19 0.83-1.72 .35
Previous ASCT 2.31 1.36-3.91 .002
OS
dUCB versus URD 1.34 0.89-2.03 .16
Age ($50 years versus <50 years) 2.86 1.02-8.01 .04
Previous ASCT 2.54 1.40-4.62 .002
Histology (myeloid versus
lymphoid)
1.65 1.13-2.43 .01
Variables taken into account included donor type (dUCB versus URD),
age ($50 years versus <50 years), patient–donor sex mismatch (M/F
versus other), previous autologous SCT, disease risk status, histology
(myeloid versus lymphoid), GVHD prophylaxis regimen (sirolimus ver-
sus no sirolimus), and year of HSCT. Displayed are results for donor
type analysis as well as other variables that have P < .10.UCBT increases the risk of EBV-PTLD [23], and
perhaps minimizing the dose of ATG or replacing
ATG with another agent might improve outcomes
without compromising engraftment. Other strategies
for preventing EBV-PTLD after UCBT include close
surveillance of EBVDNA, preemptive or prophylactic
therapy with rituximab [24], and cellular therapy with
EBV-directed third-party cytotoxic T cells in refrac-
tory cases [25,26].
There were 2 cases of intracranial hemorrhage in
the patients experiencing NRM. The first was
a 55-year-old male with CLL who experienced a head-
ache on day 120 after dUCB and was found to have
acute bilateral subdural hematomas. He had been
managed with standard institutional transfusion crite-
ria and had not experienced any trauma or significant
hypertension. He was not offered surgical intervention
and died shortly thereafter. The second patient was
a 47-year-old female with acute lymphoblastic leuke-
mia in remission for .9 months after dUCBT and
receiving high-dose steroid therapy for presumed
bronchiolitis obliterans. She suffered a fall at home
that produced head trauma and acute subdural hema-
toma. Despite emergency surgical intervention, she
did not survive.
Interestingly, there were also 2 cases of donor cell–
derived myeloid malignancies in our series. One
patient developed MDS after undergoing RIC
dUCBT for non-Hodgkin lymphoma, and another
patient was diagnosed with MDS/myeloproliferative
disease overlap syndrome [15]. Whether donor-
derived myeloid malignancies develop at a higher
frequency after UCBT compared with conventional
adult URD HSCT is unclear, and this undoubtedly
will be a topic of future investigation given the
inherent scientific and ethical issues at play.
The present study is clearly limited by its retro-
spective nature, the relatively small size of the dUCBT
cohort, and baseline imbalances between the 2 cohorts.
The age distribution of patients differed considerably,
with 80% of the patients in the URD group age $50
years compared with only 56% of the dUCB group.
Underlying diagnoses and previous autologous stem
cell transplantation were similar in the 2 groups, how-
ever. Nevertheless, there were other likely differences
not accounted for, including different patient ethnic-
ities, physician selection and preferences, and
enrollment on specific protocols. Information for
calculating the pretransplantation comorbidity index
for all patients was not available, and many underlying
diseases are included in this analysis. In addition,
conditioning regimens and GVHD prophylaxis were
clearly different in the 2 cohorts, due to the different
stem cell sources and ongoing protocols. Even with
a propensity score analysis, it would be difficult to
draw firm conclusions given the baseline differences
in the 2 groups, and a much larger study is needed to
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Figure 4. Causes of NRM after dUCBT (n 5 16). ‘‘Donor onc’’ refers
to donor cell-derived malignancy.
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Figure 6. OS (PFS) for patients undergoing dUCBT and URD RIC
HSCT.
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equivalent.
Although our observations are intriguing, their
real value is in stimulating further investigation in
larger cohorts, perhaps in multicenter or registry anal-
yses. A prospective randomized trial comparing
dUCBT and URD HSCT would be ideal, but logisti-
cal issues associated with HLA-matching require-
ments, donor availability, financial contraints, and
delays associated with donor evaluation will make
such a study challenging. A multicenter, large, ran-
domized trial comparing dUCB and haploidentical
donors in the RIC setting is currently in the planning
stage through the Blood and BoneMarrowTransplan-
tation Clinical Trials Network (BMT CTN). In this
and other studies, other significant outcomes not in-
cluded in this analysis, such as differences in cost and
quality of life, should be taken into account when com-
paring donor sources.Years
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Figure 5. PFS for patients undergoing dUCBTand URD RIC HSCT.In summary, despite the limitations of the present
analysis, our results suggest that for patients undergo-
ing RIC HSCT without a well-matched adult donor,
the use of 2 partially matched UCB units appears to
be a suitable alternative with comparable survival
outcomes. Specifically, the similar rate of relapse and
a much lower incidence of chronic GVHD after
dUCBT is compelling, but infectious complications
and EBV-PTLD remain significant barriers to the suc-
cess of this approach.ACKNOWLEDGMENTS
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